NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.
Poster Presentation Title: | Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors |
Abstract Number: | 1174 / 4 |
Presenter: | Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA |
Poster Session Date and Time: | Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT |
Location: | Poster Section 27 |
Trial in Progress Title: | A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 -wild type and MDM2 -amplified advanced or metastatic solid tumors (MANTRA-2) |
Abstract Number: | CT123/5 |
Presenter: | Ecaterina I. Dumbrava, M.D., Medical Oncologist, The University of Texas MD Anderson Cancer Center |
Session Date and Time | Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT |
Location: | Poster Section 34 |
Trial in Progress Title: | MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas |
Abstract Number: | CT235/6 |
Presenter: | Mrinal M. Gounder, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center |
Session Date and Time: | Tuesday, April 12, 2022, 1:30 p.m. – 5:00 p.m. CT |
Location: | Poster Section 36 |
A copy of the presentation materials can be accessed by visiting the " Resources ” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com